Sovremennye podkhody k terapii yuvenil'nogo artrita


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Juvenile arthritis (JA) is a chronic inflammatory disease of the joints, which in the absence of adequate early treatment leads to severe destructive changes, severe functional impairments, disability, and in some cases - fatal outcome. Current methods of treatment of JA are based on the use of the most effective drugs to achieve the development of a stable remission and promising long-term outcomes of the disease. An integrated approach with the rational use of conventional therapy, including symptom-modifying and disease-modifying anti-inflammatory drugs, as well as the timely use of innovative genetically engineered biological agents (especially in patients refractory to conventional therapy) are the key to improving the prognosis and quality of life of patients with JA.

Full Text

Restricted Access

About the authors

S. O Salugina

Email: pafon1@yandex.ru

E. S Fedorov

References

  1. Horneff G. Treatment options with biologics for juvenile idiopathic arthritis // Int. J. Clin. Rheum. - 2011. - Vol. 6(3). - P. 1-19.
  2. Клинические рекомендации для педиатров. Детская ревматология. Ювенильный артрит/ Под ред. А.А. Баранова, Е.И. Алексеевой. М., 4. 2013. -117 с.
  3. Petty R.E., Southwood T.R., Manners P., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001 // J. Rheumatol. - 2004. - Vol. 31. - P. 390-92. Cassidy J.T., Petty R.E., Laxer R.M., et al. Textbook of pediatric rheumatology. 6th ed. Phila delphia: Elsevier Saunders, 2011. - P. 71-126.
  4. Клинические рекомендации. Ревматология. 2-е изд. / Под ред. Е.Л. Насонова. М., 2010.-С. 231-70.
  5. Haines K.A. Juvenile idiopathic arthritis. Therapies in the 21st Century // Bulletin of the NYU Hospital for Joint Diseases. - 2007. - Vol. 65(3). — P. 205-11.
  6. Ravelli A., Lattanzi B., Consolaro A., et al. Glucocorticoids in paediatric rheumatology // Clin. Exp. Rheumatol. — 2011. — Vol. 29(68). — P. 148—52
  7. Ravelli A., Lattanzi B., Consolaro A., et al. Glucocorticoids in paediatric rheumatology // Clin. Exp. Rheumatol. — 2011. — Vol. 29(68). — P. 148—52.
  8. Lanni S., Bertamino M., Consolaro A., et al. Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis // Rheumatology. — 2011. — Vol. 50. — P. 1627—34.
  9. Huppertz H.I., Tschammler A., Horwitz A.E., et al. Intraarticular corticosteroids for chronic arthritis in children: efficacy and effects on cartilage and growth // J. Pediatr. — 1995. — Vol. 127. — P. 317—21.
  10. Никишина И.П., Родионовская С.Р. Метотрексат в терапии ювенильного артрита. Пособие для врачей. М., 2006. 36 с.
  11. Carvounis P.E., Herman D.C., Cha S., et al. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis. A synthesis of the literature // Graefes. Arch. Clin. Exp. Ophthalmol. — 2006. — Vol. 244. — P. 281—90.
  12. Литвицкий П.Ф. Патофизиология. Учебник для вузов. М., 2003. — С. 142—201.
  13. Насонов Е.Л. Новые направления фармакотерапии ревматических заболеваний -ингибиция интерлейкина 6 и интерлейкина 17 // Современная ревматология. — 2013. — № 3. — С. 5—14.
  14. Федоров Е.С., Салугина С.О., Кузьмина Н.Н. Роль цитокиновой сети в регуляции воспаления при различных вариантах ювенильного артрита // Научно-практическая ревматология. — 2009. — № 3. — С. 74—89.
  15. Prieur A.M., Kaufmann M.T., Griscelli C., et al. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis // Lancet. — 1987. — Vol. 2. — P. 1240—42.
  16. Prieur A.M., Roux Lombard P., Dayer J.M. Dynamics of fever and the cytokine network in systemic juvenile arthritis // Rev. Rheum. Engl. Ed. — 1996. — Vol. 63. — P. 163—70.
  17. De Benedetti F., Martini A. Is systemic juvenile rheumatoid arthritis an interleukin-6 mediated disease?//J. Rheumatol. — 1998. — Vol. 25. — P. 203-07.
  18. Rooney M., David J., Symons J., et al. Inflammatory cytokine response in juvenile chronic arthritis // Br. J. Rheumatol. — 1995. — Vol. 34. — P. 454—60.
  19. De Benedetti F. Inflammatory cytokines in the pathogenesis and treatment of systemic juvenile idiopathic arthritis // Pediatric Rheumatology Online J. — 2005. — Vol. 3. — P. 122—36.
  20. Pascual V., Allantaz F., Arce E., et al. Role of interleukin-1 (IL-1) in the patogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade // J. Experimental Medicine. — 2005. — Vol. 201. — P. 1479—86.
  21. Muller K., Herner E.B., Stagg A., et al. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis // Br. J. Rheumatol. — 1998. — Vol. 37(5). — P. 562—69.
  22. Roony M., Varsani K., Martin P., et al. Tumor necrosis factor alpha and it soluble receptor in juvenile chronic arthritis // Rheumatology. — 2000. — Vol. 39. — P. 432—38.
  23. Mangge H., Kenzian H., Gallistl S., et al. Serum cytokines in Juvenile Rheumatoid Arthritis. Correlation with Convential Inflammatiom Parametrs and Clinical Subtypes // Arthritis & Rheumatism. — 1995. — Vol. 3(2). — P. 211—20.
  24. Александрова Е.Н., Насонов Е.Л. Иммунопатология ревматоидного артрита. В кн. Генно-инженерные биологические препараты в лечении ревматоидного артрита / Под ред. Е.Л. Насонова. М., 2013. — С. 19-46.
  25. Muzzaffer M.A., Dayer J.M., Feldman B.M., et al. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin-1 receptor antagonist reflect heterogeneity of the subgroup of juvenile rheumatiod arthritis // J. Rheumatol. — 2002. — Vol. 29. — P. 1071—78.
  26. Ozen S., Saatci N., Bakkaroglu A., et al. Interleukin-1,-6,-8 Levels In Juvenile Chronic Arthrititis // Clinical Rheumatology. — 1997. — Vol. 16(2). — P. 173—78.
  27. Просвиров Е.Ю., Кельцев В.А., Рязанов В.В. и др. Морфофункциональные особенности иммунной системы при хронических артритах у детей // Научно-практическая ревматология. 2003. — № 2. — Прил. — С. 86.
  28. Wallace C.A. Developing standards of care for patients with juvenile idiopathic arthritis // J. Rheumatology. — 2010. — Vol. 49. — P. 1213—14.
  29. Davies K., Cleary G., Foster H., et al. BSPAR Standards of care for children with juvenile idiopathic arthritis // J. Rheumatology. — 2010. — Vol. 49. — P. 1406—408.
  30. Ringold S., Weiss P.F., Beukelman T., et al. 2013 Update of the 2011 American College of Rheumatology Recomendations for the Treatment of juvenile idiopathic arthritis. Recomendations for the medical therapy of children with juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications // Arthritis Rheum. — 2013. — Vol. 65(10). — P. 2499—512.
  31. Beukelman T., Patkar N.M., Saag K.G., et al. 2011 American College of Rheumatology Recomendations for the Treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features // Arthritis Care Res. (Hoboken). — 2011. — Vol. 63. — P. 465—82.
  32. Yokota S., Imagawa T., Mori M., et al. Efficacy and safety of tocilizumab in patient with system-ic-onset juvenile rheumatoid arthritis: a randomized, double-blind. placebo-controlled in juvenile rheumatoid arthritis // Lancet. — 2008. — Vol. 371. — P. 998—1006.
  33. De Benedetti F., Brunner H.I., Ruperto N., et al. Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis // N. Engl. J. Med. — 2012. — Vol. 367. — P. 2385—95.
  34. Ruperto N., Lovell D.J., Quartier P., et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled withdrawal trial // Lancet. — 2008. — Vol. 372. — P. 383—91.
  35. Lovell D.J., Giannini E.H., Reiff A., et a Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group // N. Engl. J. Med. — 2000. — Vol. 342. — P. 763—69.
  36. Lovell D.J., Giannini E.H., Reiff A., et al. Longterm efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial // Arthritis Rheum. — 2003. — Vol. 48. — P. 218—26.
  37. Lovell D.J. Update on treatment of arthritis in children. New Treatments, new Goals // Bulletin of the NYU Hospital for Joint Diseases. — 2006. — Vol. 64(1). — P. 72—6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies